Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Apicore LLC Announces the Second Successful Inspection by FDA of Its Active Pharmaceutical Ingredient (API) Site in Somerset, New Jersey

By Pharmaceutical Processing | January 13, 2009

Apicore LLC has announced that the FDA completed an inspection of its kilo-scale API manufacturing site in Somerset, New Jersey from December 12, 2008 to December 15, 2008, according to Compliance Program 7356.002F, “Drug Manufacturing Inspections for Bulk Pharmaceutical Chemicals.” This was the second successful inspection of the site since 2006. The company, established in 2005, provides process development and manufacturing services according to ICH guidelines related to new chemical entities (NCE) for new drug development clients or existing APIs for off-patent drug products. Specializing in complex chemistry, with a particular expertise in carbohydrate chemistry, Apicore offers a total service package including synthetic route screening, process optimization, scale-up and validation, analytical method development and validation, stability studies and preparation of documentation for submission to regulatory authorities. Mr. Ambrose Stafford, Vice President, Apicore LLC said, “We’re very proud that after just four years in operation our team has demonstrated a culture of GMP compliance and technical excellence. Our track record gives our clients confidence. Our facility in the United States enables us to cooperate efficiently with our clients’ teams to achieve our common objectives of on-time supply of clinical trial materials and prompt approval of our client’s drug product filings. The multi-ton facility that we’re constructing in Vadodara, India creates a low-cost base for manufacturing larger volumes than can be produced at our New Jersey site. Managing the total operation from the United States enables us to provide the combination of excellent service and low costs that our customers demand. We look forward to further expanding small-scale API manufacturing in New Jersey and to bringing our multi-ton plant in Vadodara on-line in the near future.”

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE